Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Cystic Fibrosis

Interventions

DRUG

Ivacaftor

Trial Locations (20)

Birmingham

Aurora

Atlanta

Indianapolis

Lexington

Boston

Detroit

Grand Rapids

Minneapolis

Kansas City

Omaha

Pittsburgh

Salt Lake City

Charlottesville

Richmond

Seattle

Vancouver

Edinburgh

Liverpool

London

All Listed Sponsors

collaborator

Cystic Fibrosis Foundation

OTHER

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01705145 - Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation | Biotech Hunter | Biotech Hunter